Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Organogenesis Holdings (ORGO) Preferred Stock Liabilities (2016 - 2026)

Organogenesis Holdings has reported Preferred Stock Liabilities over the past 5 years, most recently at $133.8 million for Q4 2025.

For Q4 2025, Preferred Stock Liabilities rose 9.29% year-over-year to $133.8 million; the TTM value through Dec 2025 reached $133.8 million, up 9.29%, while the annual FY2025 figure was $133.8 million, 9.29% up from the prior year.
Preferred Stock Liabilities for Q4 2025 was $133.8 million at Organogenesis Holdings, up from $130.9 million in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $133.8 million in Q4 2025 and troughed at $122.4 million in Q4 2024.